Key result
IVIG therapy for Guillain-Barre is linked to reversible corpus callosum splenial lesions and encephalopathy.
Why the study?
Reversible corpus callosum splenial lesions have varied etiologies, but their occurrence after intravenous immunoglobulin therapy for Guillain-Barre syndrome is rare and not well described.
Case Report (n=1)
IVIG therapy for Guillain-Barre syndrome may rarely cause reversible corpus callosum splenial lesions with encephalopathy.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to rare reversible IVIG encephalopathy; single case leaves open causality and incidence.
Reversible corpus callosum splenial (CCS) lesions have been described in patients with varied etiologies. The most common causes of previously reported reversible focal lesions of the CCS are viral encephalitis, antiepileptic drug toxicity/withdrawal, and metabolic disorders. Intravenous immunoglobulin (IVIG) therapy is used for different immune-mediated diseases. It is generally safe, and serious adverse reactions are uncommon. We presented a rare case of disturbed consciousness with reversible CCS lesions after IVIG therapy for Guillain-Barre syndrome in an adult woman. In this case, we believe that IVIG therapy caused reversible CCS lesions with encephalopathy and probably result of cytotoxic edema and/or cerebral arterial vasospasm.
No takes yet. Share an insight, caveat, or question.
Uygur-Kucukseymen et al. (2017) conducted a case report in Guillain-Barre syndrome (n=1). Intravenous immunoglobulin (IVIG) therapy was evaluated on Reversible corpus callosum splenial (CCS) lesions with encephalopathy. Intravenous immunoglobulin therapy for Guillain-Barre syndrome was associated with the development of reversible corpus callosum splenial lesions and encephalopathy in an adult woman.
Synapse has enriched 10 related papers. Consider them for comparative context: